The DEA proposed moving cannabis from Schedule I to Schedule III in May 2024, and legal cannabis retail sales reached $30.1 billion that year, up 4.5% from 2023, according to Whitney Economics. Public relations for cannabis and CBD companies has to work around real platform and legal limits, not old assumptions. Here is the strategy that works now.
What Changed When the DEA Proposed Rescheduling Cannabis?
The DEA's proposed move from Schedule I to Schedule III changed the regulatory story cannabis companies can credibly tell, even though it has not yet changed federal law.
The proposal drew an unprecedented 43,000 public comments during its 2024 review period, with roughly 69% supporting rescheduling to Schedule III or a less restrictive category. That volume of public engagement is itself a story cannabis companies can use in press outreach, separate from the outcome of the rule itself, since it shows a level of mainstream attention the industry did not have five years ago.
How Should Cannabis Companies Talk About Product Claims?
Cannabis and CBD companies should talk about product claims in terms of what they can substantiate, since regulators treat unproven health claims as enforcement targets, not marketing copy.
The FTC requires objective health claims to carry appropriate substantiation, and the FDA continues enforcement against CBD products marketed with unapproved therapeutic claims. Messaging built around ingredients, testing, sourcing, and intended use avoids that risk; messaging that implies a product treats or cures a condition does not.
What Does Real Cannabis PR Look Like?
Real cannabis PR replaces paid advertising, which most platforms restrict, with earned content publishers want to run on their own channels.
5W built original recipe and self-care content for CBDistillery and placed it directly with lifestyle publishers' social teams rather than pitching branded ads. The campaign generated 12.9 million social media impressions across 10 placements on the Instagram, Facebook, and TikTok channels of Byrdie, Thrillist, and Her Campus, at no media cost, because the content itself was what the platforms wanted to publish.
How Should Cannabis Brands Handle Platform and Ad Restrictions?
Cannabis brands should map what they are legally allowed to say against where they are allowed to say it before building any campaign, since the two restrictions do not follow the same rules.
Google Ads still prohibits recreational marijuana advertising in the United States, with a narrow exception for certified topical hemp-derived CBD products under 0.3% THC in select states. Every social platform sets its own separate cannabis policy. A campaign built before that mapping is done risks a rejected ad account or a takedown mid-flight.
The Bottom Line on Cannabis Tech Public Relations
Cannabis PR works when it treats regulatory limits as a planning input rather than an afterthought: substantiate every product claim, build earned content publishers actually want, and map platform rules before committing budget. Brands doing this now are building the credibility the industry's growing mainstream attention makes possible.
Cannabis, hemp, and CBD brands need marketing built around what they can actually say and where they can say it. 5W runs AI Search (GEO) programs for brands across consumer, B2B, financial services, healthcare, and technology: building the machine-readable footprint that gets brands cited, not just ranked. Learn more at 5W's cannabis marketing practice.
